Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in BCRX — Biocryst Pharmaceuticals Inc

CIK 1423053 MIAMI, FL
Back to BCRX Full portfolio

Position in BCRX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$17,591,600
+$7,893,167 QoQ
Shares Held
1,759,160
+72.7% QoQ
Ownership
0.688%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#38
of 316 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in BCRX Over Time

Shares Held

Position Value (USD)

Derivatives in BCRX

reported options exposure · as of Jun 30, 2026
CallValue
$2,322,000
CallShares
232,200
PutValue
$1,450,000
PutShares
145,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $1,255,121,114 across 64 Drug Manufacturers - Specialty & Generic names. BCRX ranks #11 (1.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ELAN
Elanco Animal Health Inc
 9,668,611 $237,944,516
2 ZTS
Zoetis Inc.
 3,188,263 $229,108,578
3 UTHR
UNITED THERAPEUTICS Corp
 304,692 $165,091,266
4 LNTH
Lantheus Holdings, Inc.
 1,376,480 $152,706,691
5 INDV
Indivior Pharmaceuticals, Inc.
 2,667,827 $109,460,941
6 ALKS
Alkermes plc.
 1,645,101 $86,203,291
7 SUPN
Supernus Pharmaceuticals, Inc.
 1,373,982 $63,903,902
8 HIMS
Hims & Hers Health, Inc.
 846,936 $29,363,271

All Filings in BCRX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,322,000 232,200
2026-06-30 $17,591,600 1,759,160
2026-06-30 $1,450,000 145,000
2026-03-31 $9,698,433 1,018,743
2026-03-31 $541,545 56,885
2026-03-31 $1,326,307 139,318
2025-12-31 $10,131,435 1,298,902
2025-12-31 $1,027,260 131,700
2025-12-31 $636,480 81,600
2025-09-30 $219,351 28,900
2025-09-30 $10,321,503 1,359,882
2025-09-30 $878,163 115,700
2025-06-30 $402,304 44,900
2025-06-30 $22,914,590 2,557,432
2025-06-30 $1,042,048 116,300
2025-03-31 $709,500 94,600
2025-03-31 $382,500 51,000
2025-03-31 $4,306,417 574,189
2024-12-31 $1,165,600 155,000
2024-12-31 $941,504 125,200
2024-12-31 $1,944,258 258,545
2024-09-30 $1,062,480 139,800
2024-09-30 $1,076,160 141,600
2024-09-30 $2,121,486 279,143
2024-06-30 $1,965,110 317,979
2024-06-30 $1,310,778 212,100
2024-06-30 $589,572 95,400
2024-03-31 $813,231 160,085
2024-03-31 $1,147,572 225,900
2024-03-31 $279,400 55,000
2023-12-31 $2,214,119 369,636
2023-12-31 $2,805,117 468,300
2023-12-31 $1,237,534 206,600
2023-09-30 $9,776,559 1,380,870
2023-09-30 $586,224 82,800
2023-09-30 $3,874,884 547,300
2023-06-30 $7,459,309 1,059,561
2023-06-30 $438,592 62,300
2023-06-30 $4,245,824 603,100
2023-03-31 $4,913,094 589,100
2023-03-31 $770,616 92,400
2023-03-31 $7,548,283 905,070
2022-12-31 $2,514,120 219,000
2022-12-31 $7,681,268 669,100
2022-12-31 $670,650 58,419
2022-09-30 $12,238,568 971,315
2022-09-30 $3,021,480 239,800
2022-09-30 $7,369,740 584,900
2022-06-30 $3,966,442 374,900
2022-06-30 $5,739,236 542,461

Report a Problem

Category
Description
Email (optional, for follow-up)